[go: up one dir, main page]

BRPI1004899B8 - composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto - Google Patents

composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto

Info

Publication number
BRPI1004899B8
BRPI1004899B8 BRPI1004899A BRPI1004899A BRPI1004899B8 BR PI1004899 B8 BRPI1004899 B8 BR PI1004899B8 BR PI1004899 A BRPI1004899 A BR PI1004899A BR PI1004899 A BRPI1004899 A BR PI1004899A BR PI1004899 B8 BRPI1004899 B8 BR PI1004899B8
Authority
BR
Brazil
Prior art keywords
compound
phosphoinositide
pharmaceutical composition
kinase inhibitor
kinase
Prior art date
Application number
BRPI1004899A
Other languages
English (en)
Inventor
Qian Changgeng
- Jung Lai Cheng
Zhai Haixiao
Cai Xiong
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of BRPI1004899A2 publication Critical patent/BRPI1004899A2/pt
Publication of BRPI1004899B1 publication Critical patent/BRPI1004899B1/pt
Publication of BRPI1004899B8 publication Critical patent/BRPI1004899B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto, composição farmacêutica e uso de um composto o presente pedido se refere a deazapurinas, tienopirimidinas e furopirimidinas com derivados à base de metade de ligação a zinco e seu uso no tratamento de doenças e distúrbios relacionados a fosfoinositida 3-quinase, tal como câncer. o presente pedido ainda se refere ao tratamento de distúrbios e doenças relativos a histona deacetilase com respeito a ambos histona deacetilase e fosfoinositida 3-quinase.
BRPI1004899A 2009-01-08 2010-01-08 composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto BRPI1004899B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14327109P 2009-01-08 2009-01-08
US61/143,271 2009-01-08
US17258009P 2009-04-24 2009-04-24
US61/172,580 2009-04-24
PCT/US2010/020495 WO2010080996A1 (en) 2009-01-08 2010-01-08 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Publications (3)

Publication Number Publication Date
BRPI1004899A2 BRPI1004899A2 (pt) 2016-04-05
BRPI1004899B1 BRPI1004899B1 (pt) 2020-08-18
BRPI1004899B8 true BRPI1004899B8 (pt) 2021-05-25

Family

ID=42316830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1004899A BRPI1004899B8 (pt) 2009-01-08 2010-01-08 composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto

Country Status (25)

Country Link
US (11) US8367663B2 (pt)
EP (1) EP2385832B1 (pt)
JP (3) JP5452617B2 (pt)
KR (2) KR20140094590A (pt)
CN (1) CN102341108B (pt)
AU (1) AU2010203512C1 (pt)
BR (1) BRPI1004899B8 (pt)
CA (1) CA2749228C (pt)
CY (1) CY1116797T1 (pt)
DK (1) DK2385832T3 (pt)
EA (1) EA024252B1 (pt)
ES (1) ES2550032T3 (pt)
HR (1) HRP20150947T1 (pt)
HU (1) HUE027615T2 (pt)
IL (2) IL213976A (pt)
ME (1) ME02230B (pt)
MX (1) MX2011007326A (pt)
PL (1) PL2385832T3 (pt)
PT (1) PT2385832E (pt)
RS (1) RS54230B1 (pt)
SG (2) SG196815A1 (pt)
SI (1) SI2385832T1 (pt)
SM (1) SMT201500226B (pt)
TW (1) TWI558710B (pt)
WO (1) WO2010080996A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150947T1 (hr) 2009-01-08 2015-10-09 Curis, Inc. Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink
US20110230476A1 (en) * 2009-09-09 2011-09-22 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
DK2615092T3 (en) * 2010-09-10 2015-09-21 Hangzhou Bensheng Pharmaceutical Co Ltd Heterocyclic AMINOBERBAMIN DERIVATIVES, PREPARATION METHOD AND USE THEREOF
EA025345B1 (ru) * 2010-11-16 2016-12-30 Эситайлон Фармасьютикалз, Инк. Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и фармацевтические композиции для лечения заболевания, обусловленного hdac6, включающие эти соединения
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
US20140206678A1 (en) * 2011-01-27 2014-07-24 Kadmon Corporation, Llc Inhibitors of mtor kinase as anti -viral agent
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
LT3111938T (lt) * 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
AU2012340869B2 (en) 2011-11-23 2017-03-02 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase C
AU2014282769A1 (en) 2013-06-21 2015-12-17 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
EP3013810A1 (en) 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
EP3054952B1 (en) 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
ES2862126T3 (es) 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
WO2015061684A1 (en) 2013-10-24 2015-04-30 Mayo Foundation For Medical Education And Research Treatment of polycystic diseases with an hdac6 inhibitor
PE20161030A1 (es) 2013-12-03 2016-11-06 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN104292242B (zh) * 2014-09-18 2017-05-17 广州必贝特医药技术有限公司 噻吩嘧啶类化合物和制剂及其制备方法和应用
EP3226903A1 (en) 2014-12-05 2017-10-11 University of Modena and Reggio Emila Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
SG11201702162PA (en) * 2014-12-11 2017-04-27 Natco Pharma Ltd 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
EA033106B1 (ru) * 2015-04-21 2019-08-30 Гуйчжоу Бэйлинг Груп Фармасьютикал Ко., Лтд. Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
EP3380476B1 (en) * 2015-11-23 2020-09-30 Council of Scientific and Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
EP3535272A4 (en) * 2016-11-02 2020-06-17 Curis, Inc. COMBINATION THERAPY WITH A PHOSPHOINOSITOL-3-KINASE INHIBITOR WITH A ZINC-BINDING PART
RU2757457C2 (ru) * 2016-11-18 2021-10-18 Систик Файбросис Фаундейшн Пирролопиримидины в качестве потенциаторов мвтр
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
NZ796735A (en) 2017-02-06 2025-12-19 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
CN108623491B (zh) * 2017-03-24 2020-12-22 联化科技股份有限公司 一种卤代苯甲酰胺化合物的制备方法
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
US11234986B2 (en) 2018-09-11 2022-02-01 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN120463720A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
MX2021009142A (es) 2019-02-06 2021-10-13 Venthera Inc Inhibidores topicos de fosfoinositol 3-cinasas.
AR120173A1 (es) * 2019-10-09 2022-02-02 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
CN115135659B (zh) * 2021-01-15 2024-03-12 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
JP7736782B2 (ja) * 2021-03-29 2025-09-09 株式会社カネカ （２－メチルピリミジン－５－イル）ボロン酸誘導体の製造方法
CN113754680B (zh) * 2021-09-28 2022-07-22 云白药征武科技(上海)有限公司 一种α氟代酰基哌嗪衍生物及其制备和应用
CN118019744A (zh) * 2021-09-30 2024-05-10 韩美药品株式会社 PIKfyve激酶抑制剂
EP4511116A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN117865979A (zh) * 2024-01-04 2024-04-12 广州必贝特医药股份有限公司 噻吩嘧啶类化合物的晶型及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
AU6410699A (en) * 1998-10-13 2000-05-01 Chris Cheah Method and system for controlled distribution of information over a network
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
WO2003076395A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
JP4725945B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MXPA05007990A (es) * 2003-01-29 2005-09-20 Takeda Pharmaceutical Compuestos de tienopirimidina y uso de los mismos.
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
US7218492B2 (en) * 2004-09-17 2007-05-15 Electronic Polymers, Inc. Devices and systems for electrostatic discharge suppression
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2522395A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7731753B2 (en) * 2005-09-01 2010-06-08 Spinal Kinetics, Inc. Prosthetic intervertebral discs
JP5021660B2 (ja) * 2005-10-24 2012-09-12 バイオメット・３アイ・エルエルシー 歯科用インプラント構成要素を製造するための方法
JP2007151829A (ja) * 2005-12-05 2007-06-21 Bridgestone Sports Co Ltd ゴルフクラブヘッド
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
CL2007001166A1 (es) * 2006-04-26 2008-01-25 Piramed Ltd Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
RU2008141356A (ru) 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k)
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
EP2061468A4 (en) 2006-09-11 2011-05-04 Curis Inc TYROSINE KINASE INHIBITORS CONTAINING ZINC BINDING CHARACTERISTIC GROUP
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033743A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
US20080234355A1 (en) * 2006-09-11 2008-09-25 Xiong Cai Dna methyl transferase inhibitors containing a zinc binding moiety
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662587C (en) * 2006-09-11 2013-08-06 Curis, Inc. Quinazoline based egfr inhibitors
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
CL2007003108A1 (es) 2006-10-28 2008-07-18 Methylgene Inc Envivo Pharmace Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
BRPI0717907A2 (pt) * 2006-12-07 2013-11-05 Genentech Inc "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
AR064155A1 (es) 2006-12-07 2009-03-18 Piramed Ltd Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
CA2680398A1 (en) 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
MX2010004260A (es) * 2007-10-16 2010-04-30 Wyeth Llc Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
EP2303886A2 (en) 2008-06-24 2011-04-06 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
HRP20150947T1 (hr) * 2009-01-08 2015-10-09 Curis, Inc. Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
MX345155B (es) 2009-10-12 2017-01-18 F Hoffmann-La Roche Ag * Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
LT3111938T (lt) * 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
SI2385832T1 (sl) 2015-10-30
CN102341108A (zh) 2012-02-01
US20170362251A1 (en) 2017-12-21
CA2749228A1 (en) 2010-07-15
EP2385832A4 (en) 2012-07-25
US8906909B2 (en) 2014-12-09
TWI558710B (zh) 2016-11-21
SG172908A1 (en) 2011-08-29
IL213976A (en) 2015-03-31
US20190352310A1 (en) 2019-11-21
US20200339593A1 (en) 2020-10-29
US20220402934A1 (en) 2022-12-22
PL2385832T3 (pl) 2016-01-29
CA2749228C (en) 2016-05-17
KR20140094590A (ko) 2014-07-30
EP2385832B1 (en) 2015-07-15
HRP20150947T1 (hr) 2015-10-09
US9725461B2 (en) 2017-08-08
KR101430424B1 (ko) 2014-08-14
US8461157B2 (en) 2013-06-11
AU2010203512C1 (en) 2013-10-17
US20250230169A1 (en) 2025-07-17
SG196815A1 (en) 2014-02-13
BRPI1004899B1 (pt) 2020-08-18
US20150203509A1 (en) 2015-07-23
US20140155595A1 (en) 2014-06-05
US8367663B2 (en) 2013-02-05
WO2010080996A1 (en) 2010-07-15
BRPI1004899A2 (pt) 2016-04-05
US11597732B2 (en) 2023-03-07
SMT201500226B (it) 2015-10-30
US20210214370A1 (en) 2021-07-15
JP2012514650A (ja) 2012-06-28
IL237727A0 (en) 2015-05-31
HK1164113A1 (en) 2012-09-21
DK2385832T3 (en) 2015-09-21
JP5762520B2 (ja) 2015-08-12
HUE027615T2 (en) 2016-10-28
IL213976A0 (en) 2011-08-31
JP2015187145A (ja) 2015-10-29
JP2014058571A (ja) 2014-04-03
AU2010203512A1 (en) 2011-08-11
US20120088764A1 (en) 2012-04-12
PT2385832E (pt) 2015-11-02
AU2010203512B2 (en) 2013-03-14
US20230227467A1 (en) 2023-07-20
CY1116797T1 (el) 2018-03-07
ES2550032T3 (es) 2015-11-04
TW201030009A (en) 2010-08-16
US10894795B2 (en) 2021-01-19
JP5452617B2 (ja) 2014-03-26
CN102341108B (zh) 2015-05-27
EA201101053A1 (ru) 2012-02-28
ME02230B (me) 2016-02-20
US11261195B2 (en) 2022-03-01
EP2385832A1 (en) 2011-11-16
KR20110112404A (ko) 2011-10-12
US20100222343A1 (en) 2010-09-02
US10676482B2 (en) 2020-06-09
EA024252B1 (ru) 2016-08-31
RS54230B1 (sr) 2015-12-31
MX2011007326A (es) 2011-10-19
US10336770B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
BRPI1004899B8 (pt) composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
ECSP11010760A (es) Derivados de quinoxalindiona
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
MX2011013306A (es) Compuestos tetraciclicos.
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BRPI0915300B8 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
UY32605A (es) Agentes antiinflamatorios como compuestos virostáticos
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
BR112012011328A2 (pt) inibidores de akt
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: CURIS, INC. (US)